Annovis Bio, Inc. (ANVS) › Cash & EquivalentsAnnovis Bio, Inc. (ANVS) — Cash & EquivalentsAnnual figures by period end, from SEC filings.2019-12-31: $1.9K2020-12-31: $8.07M2021-12-31: $45.69M2022-03-31: $42.67M2022-06-30: $35.97M2022-09-30: $31.99M2022-12-31: $28.38M2023-12-31: $5.75M2024-12-31: $10.55M2025-12-31: $19.53M$19.53M2019-12-31Cash & Equivalents (USD)2025-12-31Period endedCash & EquivalentsChange YoYSource filing2025-12-31$19.53M+85.1%2026-03-13Balance as of period end2024-12-31$10.55M+83.4%2026-03-13Balance as of period end2023-12-31$5.75M-79.7%2025-03-21Balance as of period end2022-12-31$28.38M—2024-03-29Balance as of period end2022-09-30$31.99M—2023-03-31Balance as of period end2022-06-30$35.97M—2023-03-31Balance as of period end2022-03-31$42.67M—2023-03-31Balance as of period end2021-12-31$45.69M+465.8%2023-03-31Balance as of period end2020-12-31$8.07M+434488.7%2022-03-02Balance as of period end2019-12-31$1.9K—2021-03-03Balance as of period endOther metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per ShareWeighted Average Diluted SharesEPS (Basic)